Immunotherapy: Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) With Anti-Mcam Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells

Authors

W Luo, New York Medical College
A Gardenswartz, New York Medical CollegeFollow
Y Chu, New York Medical College
J Rosenblum, New York Medical College
J Ayello, New York Medical CollegeFollow
W Overwijk
T Cripe
K Cassady
D A. LeeFollow
M S. Cairo, New York Medical College

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

2022

DOI

10.1016/S1465-3249(22)00301-2

Journal Title

Cytotherapy

Department

Pediatrics

Abstract

Background & Aim: Background Pediatric patients with metastatic ES, OS and NB have a dismal average 5-year survival (

Recommended Citation

Luo, W., Gardenswartz, A., Chu, Y., Rosenblum, J., Ayello, J., Overwijk, W., Cripe, T., Cassady, K., Lee, D. A., & Cairo, M. S. (2022). Immunotherapy: Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) With Anti-Mcam Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells. Cytotherapy, 24 (5), S109. https://doi.org/10.1016/S1465-3249(22)00301-2